SIRT1 Suppresses Doxorubicin-induced Cardiotoxicity by Regulating the Oxidative Stress and P38MAPK Pathways
Overview
Cell Biology
Pharmacology
Authors
Affiliations
Background: SIRT1, which belongs to the Sirtuin family of NAD-dependent enzymes, plays diverse roles in aging, metabolism, and disease biology. It could regulate cell survival and has been shown to be a protective factor in heart function. Hence, we verified the mechanism by which SIRT1 regulates doxorubicin induced cardiomyocyte injury in vivo and in vitro.
Methods: We analyzed SIRT1 expression in doxorubicin-induced neonatal rat cardiomyocyte injury model and adult mouse heart failure model. SIRT1 was over-expressed in cultured neonatal rat cardiomyocyte by adenovirus mediated gene transfer. SIRT1 agonist resveratrol was used to treat the doxorubicin-induced heart failure mouse model. Echocardiography, reactive oxygen species (ROS) production, TUNEL, qRT-PCR, and Western blotting were performed to analyze cell survival, oxidative stress, and inflammatory signal pathways in cardiomyocytes.
Results: SIRT1 expression was down-regulated in doxorubicin induced cardiomocyte injury, accompanied by elevated oxidative stress and cell apoptosis. SIRT1 over-expression reduced doxorubicin induced cardiomyocyte apoptosis with the attenuated ROS production. SIRT1 also reduced cell apoptosis by inhibition of p38MAPK phosphorylation and caspase-3 activation. The SIRT1 agonist resveratrol was able to prevent doxorubicin-induced heart function loss. Moreover, the SIRT1 inhibitor niacinamide could reverse SIRT1's protective effect in cultured neonatal rat cardiomyocytes.
Conclusions: These results support the role of SIRT1 as an important regulator of cardiomyocyte apoptosis during doxorubicin-induced heart injury, which may represent a potential therapeutic target for doxorubicin-induced cardiomyopathy.
Zhang S, Yang Y, Lv X, Zhou X, Zhao W, Meng L Int J Mol Sci. 2024; 25(22).
PMID: 39596439 PMC: 11594621. DOI: 10.3390/ijms252212376.
Li W, Xu K, Lan M, Gao J, Dou L, Yang Y Int J Biol Sci. 2024; 20(14):5396-5414.
PMID: 39494326 PMC: 11528453. DOI: 10.7150/ijbs.97418.
Alkandahri M, Sadino A, Pamungkas B, Oktoba Z, Arfania M, Yuniarsih N Adv Pharmacol Pharm Sci. 2024; 2024:8907717.
PMID: 39377015 PMC: 11458287. DOI: 10.1155/2024/8907717.
Alherz F, El-Masry T, Oriquat G, Elekhnawy E, Al-Shaalan N, Gaballa M Pharmaceuticals (Basel). 2024; 17(9).
PMID: 39338308 PMC: 11435365. DOI: 10.3390/ph17091144.
Gao F, Xu T, Zang F, Luo Y, Pan D Drug Des Devel Ther. 2024; 18:4089-4116.
PMID: 39286288 PMC: 11404500. DOI: 10.2147/DDDT.S469331.